Budget impact analysis of apixaban to treat and prevent venous thromboembolism in Italy

Marco Bellone, Roberto Di Virgilio, Paolo Di Rienzo

DOI: https://doi.org/10.7175/fe.v17i3.1280


BACKGROUND: Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary embolism (PE), is a serious vascular condition associated to high economic and clinical burden. Apixaban, a Novel Oral Anticoagulant (NOAC) has shown non-inferiority efficacy versus the current standard of care (low molecular weight heparin [LMWH]/vitamin K antagonist [VKA]) in the acute treatment and prevention of VTE and a significant reduction in the risk of bleeding.
AIM: Evaluate the economic impact of the use of apixaban for treatment and prevention of DVT and PE from the perspective of the Italian National Health System (NHS).
METHODS: A budget impact model was adapted in order to compare clinical outcomes and economic consequences associated to apixaban vs. LMWH/VKA and others NOACs over a three-year time horizon in the Italian setting. In the analysis two scenario were compared: status quo scenario without apixaban and an alternative scenario with apixaban. Only direct healthcare costs have been considered.
RESULTS: Assuming a population of patients receiving apixaban over the first 3 years equal to 20,957, the introduction of apixaban is associated to an incremental saving of € 821,748 in the first years, € 1,250,454 in the second year, and € 1,866,466 in the third year. The total net saving over the 3-year period is € 3,938,668, which is a 2.47% decrease from the total budget for the status quo scenario without apixaban. This saving is mainly due to reduced VTE events and bleeds by apixaban. Indeed apixaban is associated with less VTE events (both fatal and non-fatal), less major bleeding and less Clinical Relevant Non Major (CRNM) bleeding with a total of 52 fatal events avoided.
CONCLUSIONS: The listing of apixaban for the treatment of VTE (both DVT and PE) and the prevention of recurrent VTE provides both significant clinical advantages, in terms of deaths and events avoided, and economical advantages, consisting in a reduction in the total expenditure on the Italian NHS.


Apixaban; Venous thromboembolism; Budget Impact; NOAC

Full Text:



  • Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy 2009; 29: 943-53; http://dx.doi.org/10.1592/phco.29.8.943
  • White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-I8; https://doi.org/10.1161/01.CIR.0000078468.11849.66
  • Spencer FA, Emery C, Lessard D, et al. The Worchester Venous Thromboembolism Study. A population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-7; https://doi.org/10.1111/j.1525-1497.2006.00458.x
  • Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-93; https://doi.org/10.1001/archinte.158.6.585
  • Cimminiello C, Filippi A, Mazzaglia G, et al. Venous thromboembolism in medical patients treated in the setting of primary care: a nationwide case-control study in Italy. Thromb Res 2010; 126: 367-72; https://doi.org/10.1016/j.thromres.2010.07.005
  • Prandoni P. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. Thromb Res 2014; 134: 227-33; https://doi.org/10.1016/j.thromres.2014.05.013
  • Kearon C, Akl EA, Comerota AJ, et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 419-94; http://dx.doi.org/10.1378/chest.11-2301
  • Ansell J, Hirsh J, Hylek E, et al.; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 160S-198S; https://doi.org/10.1378/chest.08-0670
  • Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-52; https://doi.org/10.1016/j.chest.2015.11.026
  • Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One 2015; 10: e0144856; https://doi.org/10.1371/journal.pone.0144856
  • Comunicato relativo al medicinale per uso umano «Eliquis» (15A03834). GU Serie Generale n.118 del 23-5-2015
  • Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808; https://doi.org/10.1056/NEJMoa1302507
  • Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708; https://doi.org/10.1056/NEJMoa1207541
  • Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health 2007; 10: 336-47; https://doi.org/10.1111/j.1524-4733.2007.00187.x
  • Sullivan SD, Mauskopf JA, Augustovski F, et al., Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014; 17: 5-14; https://doi.org/10.1016/j.jval.2013.08.2291
  • ISTAT – Istituto Nazionale di Statistica. Available at: http://dati.istat.it/Index.aspx (last accessed April 2016)
  • Cohen AT, Hamilton M, Bird A, et al. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One 2016; 11: e0160064; https://doi.org/10.1371/journal.pone.0160064
  • Task Force sull’Embolia Polmonare. Linee guida per la diagnosi ed il trattamento dell’embolia polmonare acuta. Ital Heart J Suppl 2001; 2: 161-99
  • Mennini F, Russo S, Marcellusi A. Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy. Farmeconomia. Health economics and therapeutic pathways 2012;13: 121-31; https://doi.org/10.7175/fe.v13i3.268
  • Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ThrombHaemost 2011; 106: 868-76; https://doi.org/10.1160/TH11-05-0358
  • Agnelli G, Verso M, Ageno W, et al.; MASTER investigators. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res 2008; 121: 605-10; https://doi.org/10.1016/j.thromres.2007.06.009
  • Tariffe delle prestazioni di assistenza ospedaliera per acuti (sistema DRG). Supplemento ordinario n. 8 alla Gazzetta Ufficiale Serie generale - n. 23 del 28-1-2013
  • Torbicki A, Perrier A, Konstantinides S, et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-315; https://doi.org/10.1093/eurheartj/ehn310
  • Nomenclatore tariffario dell’assistenza specialistica ambulatoriale. Tariffa Unica Convenzionale. Edizione 2013
  • Ministero della Salute. Progetto Mattoni SSN. Pronto Soccorso e Sistema 118. “Proposta metodologica per la valutazione dei costi dell’emergenza” Roma 2007
  • Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013; 347: f5133; https://doi.org/10.1136/bmj.f5133
  • National Institute for Health and Care Excellence. Final Appraisal determination – Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. Technology appraisal guidance [TA341]. Available at: https://www.nice.org.uk/guidance/ta341 (last accessed April 2016)
  • Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011; 14: 417-28; https://doi.org/10.1016/j.jval.2011.04.002
  • Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Hoboken, NJ: Wiley, 2004


  • There are currently no refbacks.

© SEEd srl